Device Industry Evaluating Impact of Japan Catastrophe
This article was originally published in The Gray Sheet
Though the long-term impact of the March 11 earthquake, tsunami and subsequent nuclear crisis in Japan remains to be seen, the device industry worked last week to respond to a number of short-term challenges presented by the evolving disaster.
You may also be interested in...
Several mobile health technology vendors joined together earlier this year to sponsor a cardiovascular disease prevention program for evacuees who survived the devastating March 11 earthquake and tsunami in Japan.
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.